The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Emerging immunotherapies for myeloma
Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines emerging immunotherapies for multiple myeloma. Immunotherapy has been a large area of research in myeloma over the last 5 years and many novel agents have been discovered. ASH 2020 will see updates from numerous ongoing trials of BCMA-directed CAR T-cell therapy, as well as emerging data from next-generation CAR T-cells. Bispecific antibodies are also being investigated. An important recent development has been the identification of GPRC5D and FcRH5 as potential myeloma targets; results from early trials targeting these antigens will be seen at ASH. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
